Healthcare utilization and 30-day in-hospital costs following brain tumor surgery: a single-center, retrospective cohort study
Clicks: 1
ID: 315755
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #31 of 42 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Brain tumors cause more than 248,000 deaths annually, and their incidence continues to rise. Despite medical advances, outcomes have improved marginally, and the associated economic burden is substantial. European spending was estimated at €37.8 billion in 2019. Although several cost drivers have been identified, robust and methodologically sound cost evaluations remain limited. This study aimed to quantify 30-day in-hospital healthcare consumption and identify cost drivers in brain tumor surgery. Methods Adult patients undergoing brain tumor surgery in 2023 at a single regional referral center were retrospectively analyzed. The primary outcome was total 30-day in-hospital costs, calculated using a bottom-up micro-costing approach. Univariable and multivariable analyses were performed to identify key cost drivers. Results A total of 322 patients (mean age 61 years; 51.2% female) were included in this study. Median length of stay (LOS) was 3 days (IQR; 2–6), and mean in-hospital costs were € 6988 per patient (SD ± € 4273). Tumor pathology was associated with significantly increased surgical costs (P = .035) but did not significantly influence overall costs (P = .376). Multivariable analysis identified surgery type, preoperative Karnofsky Performance Status, total length of stay (LOS), Intensive Care Unit (ICU) LOS, and Clavien-Dindo complication grade as independent cost drivers. Repeat surgery, readmission, and 30-day mortality further increased costs. Conclusions Thirty-day in-hospital costs following brain tumor surgery are substantial, mainly driven by operative and hospitalization factors. Identifying modifiable cost determinants is essential for developing targeted interventions to improve efficiency and optimize resource utilization.
| Reference Key |
openalex_W7163378469
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Floor R Pijl, Maik L Landers, Tanvi Kamra, Yasmine Zallali, Karan O T Ramcharan, Maaike J. Vos, Thijs Van Der Vaart, Johan A F Koekkoek, Jaap Zindler, Mar Rodríguez‐Girondo, Rob J A Nabuurs, Marike L D Broekman, Wouter A. Moojen, Wilco C. Peul, Jeroen T J M Van Dijck, Melissa Kerkhof, Rishi Nandoe Tewarie |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag053
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.